Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 166Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma 23Neoplasms, Plasma Cell 21Leukemia 21Recurrence 20Burkitt Lymphoma 18Lymphoma, Non-Hodgkin 15Neoplasms 14Lymphoma, Mantle-Cell 14Immunoglobulin Light-chain Amyloidosis 14Nausea 13Lymphoma, Large B-Cell, Diffuse 13Vomiting 12Breast Neoplasms 12Hodgkin Disease 11Waldenstrom Macroglobulinemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Amyloidosis 9Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Acute 8Smoldering Multiple Myeloma 7Neoplasm Metastasis 7Leukemia, Biphenotypic, Acute 6Hematologic Neoplasms 6Blast Crisis 6Prostatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, B-Cell 5

Interventions

Dexamethasone 4Methods 2Electroencephalography 2selinexor 1pomalidomide 1ixazomib 1Transurethral Resection of Bladder 1Telemedicine 1Tablets 1Surgical Procedures, Operative 1Standard of Care 1Neurofeedback 1Melphalan 1Mass Screening 1Magnetic Resonance Imaging 1Lysine Acetyltransferase 5 1Hypnosis 1Hormones 1Exercise 1Ethanol 1Drug Delivery Systems 1Cyclophosphamide 1Control Groups 1Cholinesterase Inhibitors 1Calcium Dobesilate 1Bortezomib 1Biopsy 1Amyloid 1Amputation, Surgical 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Alzheimer Disease × Calcium Dobesilate × Clear all
NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡